Lixte Biotechnology (NASDAQ:LIXT) Releases Quarterly Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) announced its quarterly earnings results on Wednesday. The company reported ($0.33) earnings per share (EPS) for the quarter, Zacks reports.

Lixte Biotechnology Price Performance

Shares of LIXT traded up $0.34 on Wednesday, reaching $4.75. The company’s stock had a trading volume of 118,311 shares, compared to its average volume of 660,311. The stock has a market capitalization of $27.09 million, a P/E ratio of -3.68 and a beta of 0.45. The stock’s 50 day simple moving average is $4.76 and its two-hundred day simple moving average is $3.29. Lixte Biotechnology has a 12-month low of $0.64 and a 12-month high of $6.26.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Wall Street Zen raised Lixte Biotechnology to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lixte Biotechnology in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.